BMI的失效与“肥胖”定义的权力操弄The Failure of BMI and the Power Play of 'Obesity' Definitions
BMI这个粗糙的工具在医学界被诟病多年，但现在人们突然意识到它“不精准”了，并不是因为医学变得仁慈，而是因为资本发现了新的认知入口。当“临床肥胖”被重新定义为一种“慢性系统性疾病”，并把指标从单纯的体重身高比扩展到腰围、器官功能障碍甚至“行走困难”时，原本处于“超重”甚至“正常体重”区间的大量人口被瞬间划入了“病人”阵营。
这在加尔通的暴力三角中是典型的 structural violence。通过重新定义什么是“病”，医疗体制在事实上完成了对身体表达的殖民。当 50% 的超重者被重新分类为肥胖患者，这意味着巨大的药企市场（如 GLP-1 类药物）获得了合法的扩张空间。这不再是关于健康的讨论，而是一场关于“谁有权定义病态”的博弈。
最讽刺的是，这种定义的扩张往往掩盖了真正的生物墙。对于女性而言，身体被定义为“肥胖”或“健康”的标准长期由男性主导的医学叙事决定。当定义权在“不精准”和“更精准”之间摇摆时，女性的身体再次成为了被量化、被诊断、被消费的客体。这次所谓的“定义更新”，不过是医疗资本在通过操纵解释权，将更多健康的人转化为终身订阅药品的共谋者。
BMI has been criticized as a crude tool for years, but the sudden realization of its 'imprecision' isn't born of medical benevolence—it's because capital found a new cognitive entry point. By redefining 'clinical obesity' as a 'chronic systemic illness' and expanding criteria from weight-to-height ratios to waist circumference and organ dysfunction, a massive population previously labeled as 'overweight' or even 'normal' is instantly drafted into the 'patient' camp.
In Galtung's Violence Triangle, this is textbook structural violence. By redefining what constitutes a 'disease,' the medical establishment effectively colonizes the expression of the body. When 50% of overweight adults are reclassified as obese, the pharmaceutical market (such as GLP-1 drugs) gains a legitimate license for expansion. This is no longer a discussion about health; it is a game of who holds the power to define pathology.
Most ironically, this expansion of definition masks the actual biological wall. For women, the standards of being 'obese' or 'healthy' have long been dictated by a masculine-centric medical narrative. As the power of definition oscillates between 'imprecise' and 'precise,' the female body remains a quantified, diagnosed, and consumed object. This 'updated definition' is merely medical capital manipulating the right of interpretation to turn more healthy individuals into complicitors of lifelong pharmaceutical subscriptions.